Abstract
We evaluated in vitro the antiproliferative activity of DPR (Fig. 1), a new cisplatin-derived compound, in combination with five conventional anticancer drugs: the antimetabolites 5-fluorouracil (5FU) and methotrexate (MTX), the alkylating agent mitomycin C (MMC), the antimicrotubule agent taxol (TAX) and the intercalating agent of the antracycline group doxorubicin (DOX), against murine P388 leukemic cells. MTT assay was used to determine growth inhibition after incubation of cells for 72 hours in the presence of single or combined drugs. The additive, synergistic or antagonistic nature of the combined drug effect was determined using the isobole method.
In our cellular model, synergism was the prevailing result observed when DPR was combined with MMC. Conversely, antagonism was observed when DPR was combined with TAX. When DPR was administered together with the other antineoplastic drugs, the final effect was dependent on the concentrations of single agents.
The study in vitro of the association between DPR and MMC was extended in vivo in BDF-1 female mice bearing ip P388 leukemic cells. Our data in vivo confirmed those obtained in vitro, demonstrating the therapeutic advantage of the association of ineffective doses of DPR (2 and 7 mg/kg) and MMC (3.2 mg/kg) over the administration of MMC alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cafaggi S, Esposito M, Parodi B, Vannozzi MO, Viale M, Pellecchia C, Fulco RA, Merlo F, Zicca A, Cadoni A, Bignardi G: Synthesis and antitumor activity of a new cisdiammineplatinum(II) complex containing procaine hydrochloride. Anticancer Res 12: 2285-2292, 1992
Viale M, Vannozzi MO, Merlo F, Cafaggi S, Parodi B, Esposito M: Cisplatin combined with the new cisplatin-procaine complex DPR: in vitroand in vivostudies. Eur J Cancer 13: 2327-2333, 1996
Viale M, Cafaggi S, Parodi B, Esposito M: Cytotoxicity and cellular accumulation of a new cis-diammineplatinum(II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 35: 371-376, 1995
Zhang JG, Esposito M, Cafaggi S, Lindup WE: Comparison of the toxicities of cisplatin and a new cisplatin-procaine complex to rat renal cortical slices. Hum Exp Toxicol 15: 59-63, 1996
Mandys V, Viale M, Vrana J, Cafaggi S, Esposito M: Neurotoxic effect of the cisplatin-procaine complex DPR studied in organotypic cultures of chick embryonic dorsal root ganglia. Anti-Cancer Drugs 9: 659-663, 1998
Viale M, Melioli G, Pasquetti W, Meta M, Cafaggi S, Esposito M: Modifications of cell cycle induced by DPR, a new platinum-triamine complex containing procaine. Int J Oncol 4: 1047-1051, 1994
Hussain RF, Nouri AME, Oliver RTD: A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160: 89-96, 1993
Geran RI, Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep 3: 1-103, 1972
Berembaum MC: What is synergy? Pharmacol Rev 41: 93- 141, 1989
Berembaum MC: Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35: 269-335, 1981
Scanlon K, Newman EM, Lu Y, Priest DG: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923-8935, 1986
Perez RP, Perez KM, Handel LM, Hamilton TC: In vitrointeractions between platinum analogs in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol 29: 430- 434, 1992
Jekunen AP, Christen RD, Shalinsky DR, Howell SB: Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69: 299-306, 1994
Lidor YJ, Shpall EJ, Peters WP, Bast RC, Jr: Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 49: 704-710, 1991
Sorenson CM, Eastman A: Mechanism of cis-diamminedichloroplatinum( II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 48: 4484-4488, 1988
Sorenson CM, Barry MA, Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. JNCl 82: 749-755, 1990
Peyrot B, Briand C, Momburg R, Sari JC: In vitromechanism study of microtubule assembly inhibition by cisdichlorodiammine-platinum(II). Biochem Pharmacol 35: 371- 375, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pastrone, I., Viale, M., Cafaggi, S. et al. Effect of the cisplatin-procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells in vitro and in vivo. Invest New Drugs 16, 297–302 (1998). https://doi.org/10.1023/A:1006228027066
Issue Date:
DOI: https://doi.org/10.1023/A:1006228027066